CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 10 of 87

Some of the metrics are blocked by your
consent settings
New Dermoscopy Pattern in Nevus‐Associated Melanomas
(Wiley, 2025-04-19)
Nelson Lobos‐Guede
;
Dan Hartmann
;
Valentina Darlic
;
Cristina Carrera
;
Llucia Alos
Melanomas can appear de novo or in association with a pre‐existing nevus. The association of melanomas with pre‐existing nevi and its role as a melanoma precursor is a controversial issue. Dermoscopy can increase melanoma's diagnostic accuracy and help us suspect nevus‐associated melanomas (NAM). Differentiating NAMs clinically and dermoscopically can be challenging. There are few published studies so far describing dermoscopic features of NAM that have differentiated from <jats:italic>de novo</jats:italic> melanomas, such as multi‐component pattern, multifocal pigmentation, atypical pigment network, regression structures, negative pigment network, irregular globules, and streaks. Here, we report four acquired compound NAMs showing a starburst pattern (SP) within the lesion. No publications have reported NAMs with melanoma components in the form of SP arising within the center of the lesion. Therefore, when faced with a compound or intradermal nevus with incipient central reticulated pigmentation, especially if there is no history of trauma or previous surgery, we must pay alert to the possibility of an early development of melanoma.
2
Some of the metrics are blocked by your
consent settings
Clinical, immunologic, and genetic characteristics of 148 patients with natural killer cell deficiency
(Elsevier BV, 2025-05)
Manar Abdalgani
;
Evelyn R. Hernandez
;
Luis A. Pedroza
;
Ivan K. Chinn
;
Lisa R. Forbes Satter
Scopus© Citations 1 2
Some of the metrics are blocked by your
consent settings
Conventional Radiotherapy Timing and Wound Complication Avoidance After Surgery for Metastatic Spine Disease. A LatAm Modified Delphi Study
(Elsevier BV, 2025-03)
Federico Landriel
;
Kevin White
;
Fernando Padilla Lichtenberger
;
Alfredo Guiroy
;
Alisson Teles
2
Some of the metrics are blocked by your
consent settings
Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections
(2024)
Angelique E Boutzoukas
;
Natalie Mackow
;
Abhigya Giri
;
Lauren Komarow
;
Carol Hill
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The CDC reported a 35% increase in hospital-onset (HO) carbapenem-resistant Enterobacterales (CRE) infections during the COVID-19 pandemic. We evaluated patient outcomes following HO and community-onset (CO) CRE bloodstream infections (BSI).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Patients prospectively enrolled in CRACKLE-2 from 56 hospitals in 10 countries between 30 April 2016 and 30 November 2019 with a CRE BSI were eligible. Infections were defined as CO or HO by CDC guidelines, and clinical characteristics and outcomes were compared. The primary outcome was desirability of outcome ranking (DOOR) 30 days after index culture. Difference in 30-day mortality was calculated with 95% CI.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among 891 patients with CRE BSI, 65% were HO (582/891). Compared to those with CO CRE, patients with HO CRE were younger [median 60 (Q1 42, Q3 70) years versus 65 (52, 74); P &lt; 0.001], had fewer comorbidities [median Charlson comorbidity index 2 (1, 4) versus 3 (1, 5); P = 0.002] and were more acutely ill (Pitt bacteraemia score ≥4: 47% versus 32%; P &lt; 0.001). The probability of a better DOOR outcome in a randomly selected patient with CO BSI compared to a patient with HO BSI was 60.6% (95% CI: 56.8%–64.3%). Mortality at 30-days was 12% higher in HO BSI (192/582; 33%) than CO BSI [66/309 (21%); P &lt; 0.001].</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>We found a disproportionately greater impact on patient outcomes with HO compared to CO CRE BSIs; thus, the recently reported increases in HO CRE infections by CDC requires rigorous surveillance and infection prevention methods to prevent added mortality.</jats:p> </jats:sec>
Scopus© Citations 1 3
Some of the metrics are blocked by your
consent settings
Exclusion criteria for intravenous thrombolysis in stroke Chameleons: An observational study
(2024)
BRUNSER RABOVICH, ALEJANDRO MICHEL
;
LAVADOS GERMAIN, PABLO MANUEL
;
MUÑOZ VENTURELLI, PAULA ANDREA
;
OLAVARRIA IANISZEWSKY, VERONICA VIVIANA
;
Eloy Mansilla
3
Some of the metrics are blocked by your
consent settings
¿Ha disminuido la colectomía por crisis de colitis ulcerosa?
(2023)
Nicolás Besser
;
Erika Chacón
;
Andrés Iglesias
;
Manuel Álvarez-Lobos
;
Carolina Pavez
1
Some of the metrics are blocked by your
consent settings
Proteasome disorders and inborn errors of immunity
(2023)
M. Cecilia Poli
<jats:title>Summary</jats:title><jats:p>Inborn errors of immunity (IEI) or primary immune deficiencies (PIDD) are caused by variants in genes encoding for molecules that are relevant to the innate or adaptive immune response. To date, defects in more than 450 different genes have been identified as causes of IEI, causing a constellation of heterogeneous clinical manifestations ranging from increased susceptibility to infection, to autoimmunity or autoinflammation. IEI that are mainly characterized by autoinflammation are broadly classified according to the inflammatory pathway that they predominantly perturb. Among autoinflammatory IEI are those characterized by the transcriptional upregulation of type I interferon genes and are referred to as interferonopathies. Within the spectrum of interferonopathies, genetic defects that affect the proteasome have been described to cause autoinflammatory disease and represent a growing area of investigation. This review is focused on describing the clinical, genetic, and molecular aspects of IEI associated with mutations that affect the proteasome and how the study of these diseases has contributed to delineate therapeutic interventions.</jats:p>
2Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Network anatomy in logopenic variant of primary progressive aphasia
(2023)
Maria Luisa Mandelli
;
Diego L. Lorca‐Puls
;
Sladjana Lukic
;
Maxime Montembeault
;
GAJARDO VIDAL, ANDREA ELIZABETH
<jats:title>Abstract</jats:title><jats:p>The logopenic variant of primary progressive aphasia (lvPPA) is a neurodegenerative syndrome characterized linguistically by gradual loss of repetition and naming skills resulting from left posterior temporal and inferior parietal atrophy. Here, we sought to identify which specific cortical loci are initially targeted by the disease (epicenters) and investigate whether atrophy spreads through predetermined networks. First, we used cross‐sectional structural MRI data from individuals with lvPPA to define putative disease epicenters using a surface‐based approach paired with an anatomically fine‐grained parcellation of the cortical surface (i.e., HCP‐MMP1.0 atlas). Second, we combined cross‐sectional functional MRI data from healthy controls and longitudinal structural MRI data from individuals with lvPPA to derive the epicenter‐seeded resting‐state networks most relevant to lvPPA symptomatology and ascertain whether functional connectivity in these networks predicts longitudinal atrophy spread in lvPPA. Our results show that two partially distinct brain networks anchored to the left anterior angular and posterior superior temporal gyri epicenters were preferentially associated with sentence repetition and naming skills in lvPPA. Critically, the strength of connectivity within these two networks in the neurologically‐intact brain significantly predicted longitudinal atrophy progression in lvPPA. Taken together, our findings indicate that atrophy progression in lvPPA, starting from inferior parietal and temporoparietal junction regions, predominantly follows at least two partially nonoverlapping pathways, which may influence the heterogeneity in clinical presentation and prognosis.</jats:p>
Scopus© Citations 10 2
Some of the metrics are blocked by your
consent settings
Integration of T‐cell clonality screening using <scp>TRBC</scp>‐1 in lymphoma suspect samples by flow cytometry
(2023)
Felipe Castillo
;
Constanza Morales
;
Biserka Spralja
;
Joaquín Díaz‐Schmidt
;
IRURETAGOYENA BRUCE, MIRENTXU INES
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The diagnosis of T‐cell non‐Hodgkin lymphomas (NHL) is challenging. The development of a monoclonal antibody specific for T‐cell receptor β constant region 1 (TRBC1) provides an alternative to discriminate clonal T cells. The aim of this study was to evaluate the diagnostic potential of an anti‐TRBC1 mAb for the identification of T‐NHL.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We performed a cross‐sectional diagnostic analytic study of samples tested for lymphoma. All samples sent for lymphoma screening were first evaluated using the standard Euroflow LST, to which a second additional custom‐designed T‐cell clonality assessment tube was added CD45/TRBC1/CD2/CD7/CD4/TCRγδ/CD3. Flow cytometry reports were compared with morphological and molecular tests.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fifty‐nine patient samples were evaluated. Within the T‐cell population, cut‐off percentages in the CD4+ cells were from 29.4 to 54.6% and from 23.9 to 52.1% in CD8+ cells. Cut‐off ratios in CD4+ T cells were from 0.33 to 1.1, and in CD8+ cells between 0.22 and 1.0. Using predefined normal cut‐off values, 18 of 59 (30.5%) samples showed a restricted expression of TRBC1. A final diagnosis of a T‐NHL was confirmed clinically and/or by histopathological studies in 15 of the 18 cases (83.3%). There were no cases of T‐NHL by morphology/IHC with normal TRBC1 expression. Non‐neoplastic patient samples behaved between predefined TRBC1 cut‐off values.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Expression of TRBC1 provides a robust method for T‐cell clonality assessment, with very high sensitivity and good correlation with complementary methods. TRBC1 can be integrated into routine lymphoma screening strategies via flow cytometry.</jats:p></jats:sec>
Scopus© Citations 3 1
Some of the metrics are blocked by your
consent settings
Hantavirus in humans: a review of clinical aspects and management
(2023)
Pablo A Vial
;
Marcela Ferrés
;
VIAL COX, MARIA CECILIA
;
Jonas Klingström
;
Clas Ahlm
Scopus© Citations 77 79

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results